ライフサイエンスコーパス: thrombospondin

1 , alphavbeta3, GPIbalpha, tissue factor, and thrombospondin.

2 he annexin A6/LDL receptor-related protein 1/thrombospondin 1 (ANXA6/LRP1/TSP1) complex in tumor cell

3 Human thrombospondin 1 (hTSP-1) is a matricellular glycoprotei

4 ARID domain-dependent, BAF-A associations at THROMBOSPONDIN 1 (THBS1) led to the concomitant upregula

5 Thrombospondin 1 (THBS1) was recently shown to promote b

6 aneous somatic Ca2+ transients, synaptogenic thrombospondin 1 (TSP-1) release, and synapse formation.

7 Basal muscle expression of thrombospondin 1 (TSP-1) was approximately 900% greater

8 ial growth factor (VEGF), but high levels of thrombospondin 1 (TSP-1), predicted liver dysfunction af

9 le expressed significantly reduced levels of thrombospondin 1 (TSP1) (P = 0.042) and increased levels

10 Thrombospondin 1 (TSP1) has been suggested as a counter

11 /-) manifested higher expression of CTGF and thrombospondin 1 (TSP1).

12 s 1, IV and XVIII as well as fibronectin and thrombospondin 1 (TSP1).

13 responsible for binding to LRP1, whereas the thrombospondin 1 and spacer domains are responsible in A

14 ion of the powerful angiostatic glycoprotein Thrombospondin 1 independently of Beclin 1 transcription

15 2), MMP9 (matrix metallopeptidase 9), TSP1 (thrombospondin 1), etc.

16 l fibroblasts through the down-regulation of thrombospondin 1, a latent transforming growth factor-be

17 ncluding vascular endothelial growth factor, thrombospondin 1, connective tissue growth factor, hepat

18 growth factor, insulin-like growth factor 2, thrombospondin 1.

19 , GFAP, inducible nitric oxide synthase, and thrombospondins 1 and 2 in DS astroglia.

20 The human matricellular glycoprotein thrombospondin-1 (hTSP-1) is released by activated plate

21 ical PspC molecule, with human matricellular thrombospondin-1 (hTSP-1).

22 rotein containing the CD36 binding domain of thrombospondin-1 (known as the TSR domain) induced assoc

23 l metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T), Cys-rich (C), and spacer (S) domai

24 on of the TGF-beta-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protei

25 We examined thrombospondin-1 (THBS1, alias TSP-1) expression in huma

26 eptidomimetic of the anti-angiogenic protein thrombospondin-1 (TSP-1 PM).

27 he capacity to bind the CD47-binding partner thrombospondin-1 (TSP-1) and that treatment of aged eryt

28 Thrombospondin-1 (TSP-1) inhibits growth factor signalin

29 Thrombospondin-1 (TSP-1) is a glycoprotein considered as

30 Thrombospondin-1 (TSP-1) is a large extracellular matrix

31 Thrombospondin-1 (TSP-1) is a multifunctional protein wh

32 Thrombospondin-1 (TSP-1) is an endogenous inhibitor of a

33 Here we show TGF-beta activation by thrombospondin-1 (TSP-1) is both required and sufficient

34 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic f

35 Increasing evidence suggests thrombospondin-1 (TSP-1), a potent proatherogenic matric

36 ntiangiogenic factors, including endostatin, thrombospondin-1 (TSP-1), and pigment epithelium-derived

37 nd re-expression of a synaptogenic molecule, thrombospondin-1 (TSP-1), apart from supporting neuronal

38 The matricellular protein, thrombospondin-1 (TSP-1), is prominently expressed durin

39 ic destruction of the antitumorigenic factor thrombospondin-1 (Tsp-1).

40 on of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

41 ts high levels of the angiogenesis inhibitor thrombospondin-1 (TSP-1).

42 spectrometry helped pinpoint this factor as thrombospondin-1 (TSP-1).

43 The Nel protein contains an N-terminal thrombospondin-1 (TSP-N) domain, five cysteine-rich doma

44 njury via a mechanism mediated by astrocytic thrombospondin-1 (TSP1) and synaptic low-density lipopro

45 -regulated STAT3 phosphorylation, astrocytic thrombospondin-1 (TSP1) and synaptic low-density lipopro

46 Thrombospondin-1 (TSP1) and TSP2 are matricellular prote

47 Here we report that soluble thrombospondin-1 (TSP1) binds to the extracellular part

48 The N-terminal thrombospondin-1 (TSP1) domain forms an unexpectedly ext

49 Plasmin (PLS) and thrombospondin-1 (TSP1) have been studied individually a

50 We confirm upregulation of thrombospondin-1 (TSP1) in Id cDKO hearts.

51 s calcineurin/NFATc1-dependent expression of thrombospondin-1 (Tsp1) in lung endothelial cells to dri

52 Thrombospondin-1 (TSP1) inhibits angiogenesis, in part,

53 Thrombospondin-1 (TSP1) is a multifunctional matricellul

54 that, upon CREB activation, HDAC2 represses thrombospondin-1 (TSP1), a potent angiogenesis inhibitor

55 ited tumor angiogenesis via the induction of Thrombospondin-1 (TSP1), and consequently suppressed tum

56 by JHDM1D-mediated epigenetic regulation of thrombospondin-1 (TSP1), forming a JHDM1D/TSP1/TGF-beta/

57 he hypothesis that the matricellular protein thrombospondin-1 (TSP1), through binding to and activati

58 lating erythrocyte microparticles (MPs), and thrombospondin-1 (TSP1).

59 A SIRP-alpha antibody that blocks thrombospondin-1 activation of SIRP-alpha mitigated the

60 AME, the guanylyl cyclase inhibitors ODQ and thrombospondin-1 also abated IR-induced IL10 expression

61 Thrombospondin-1 also stimulated phosphorylation of p47(

62 CD47 is a signaling receptor for thrombospondin-1 and an attractive therapeutic target be

63 ncreased expression levels of antiangiogenic thrombospondin-1 and inhibited S1177 phosphorylation of

64 Therefore, thrombospondin-1 and its receptor CD47 may be useful tar

65 at least in part through down-regulation of thrombospondin-1 and plasminogen activator inhibitor typ

66 Here, we report a novel interaction between thrombospondin-1 and SIRP-alpha on nonphagocytic cells.

67 can also be heterotypic-for example, between thrombospondin-1 and thrombospondin-5.

68 that exogenous decorin induced expression of thrombospondin-1 and TIMP3, two powerful angiostatic age

69 Binding studies with isolated human thrombospondin-1 and various Hic domains suggest that th

70 al cells returned the antiangiogenic protein thrombospondin-1 as a common target of both miRNAs.

71 Overall, these results suggest that thrombospondin-1 binding to SIRP-alpha on nonphagocytic

72 In cell-free experiments, thrombospondin-1 bound SIRP-alpha.

73 The thrombospondin-1 concentrations in ST-Elevation Myocardi

74 These data demonstrate that thrombospondin-1 exerts CD47-dependent and -independent

75 Only the CD47-binding domain of thrombospondin-1 exhibits this activity.

76 We have uncovered a novel role of thrombospondin-1 in modulating production and activation

77 In rodent aortic rings, treatment with thrombospondin-1 increased the production of superoxide

78 CD47, CD36, and integrin-binding domains of thrombospondin-1 independently enhance the inflammasome-

79 Thrombospondin-1 is a glycoprotein with multiple biologi

80 Thrombospondin-1 is a stress protein typically secreted

81 ed previously that the matricellular protein thrombospondin-1 is upregulated in IRI.

82 nal tubular epithelial cells, treatment with thrombospondin-1 led to phosphorylation of SIRP-alpha an

83 Serum thrombospondin-1 level was significantly increased after

84 PEDF overexpression suppressed thrombospondin-1 levels in vitro.

85 te (p < 0.02) but not with changes in plasma thrombospondin-1 levels.

86 Physiological concentrations of thrombospondin-1 limit the induction by lipopolysacchari

87 Disintegrin-like and Metalloproteinase with Thrombospondin-1 motifs) protein family, cleaves large p

88 marrow-derived macrophages that lack either thrombospondin-1 or CD47 exhibit diminished induction of

89 Blockade of thrombospondin-1 or CD47 provides local radioprotection

90 M organization, we find that accumulation of thrombospondin-1 or thrombospondin-5 puncta within cell-

91 e evolved from cell-SELEX that can recognize thrombospondin-1 protein in human plasma samples.

92 design of an M55-aptasensor for quantifying thrombospondin-1 protein in plasma samples.

93 Thrombospondin-1 regulates inflammation by engaging seve

94 nhibition can be explained by the ability of thrombospondin-1 to disrupt the interaction between CD47

95 Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy

96 EOC cells with a recombinant version of the thrombospondin-1 type I repeats (3TSR) induced more apop

97 The KD value of the aptamer M55 binding to thrombospondin-1 was determined as 0.5 +/- 0.2 muM with

98 ty group box-1 protein, chemokine CXCL4, and thrombospondin-1 were significantly higher in patients w

99 Here, we found that both CD47 and its ligand thrombospondin-1 were upregulated after renal IRI in mic

100 telet-derived growth factor, collagen I, and thrombospondin-1) were higher in PEDF-null mice at basel

101 s related to decreased protein expression of thrombospondin-1, an antiangiogenic regulator.

102 essel maturation, including PDGFb, TGF-beta, thrombospondin-1, and CXCL10; consistently, they were ch

103 argo, including von Willebrand factor (VWF), thrombospondin-1, and platelet factor 4.

104 DEB fibroblasts decreased type XII collagen, thrombospondin-1, and Wnt-5A expression, reduced tumor c

105 roblasts led to increased type XII collagen, thrombospondin-1, and Wnt-5A, while reexpression of wild

106 on of ancillary C-terminal disintegrin-like, thrombospondin-1, cysteine-rich, and spacer domains to b

107 enuated in vitro antiangiogenic responses to thrombospondin-1, including blockade of migration, tube

108 lasma levels of von Willebrand factor (VWF), thrombospondin-1, myeloperoxidase, ADAMTS-13, and active

109 d messenger RNA expression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and

110 Furthermore, the endogenous ligand thrombospondin-1, responsible for the synaptogenic prope

111 In the absence of thrombospondin-1, retinal neovascular membranes are mark

112 -898 mimics the antiangiogenic properties of thrombospondin-1, so we hypothesized that ABT-898 will p

113 -regulated the potent angiogenesis inhibitor thrombospondin-1, thereby triggering a negative feedback

114 tein expression of anti-angiogenic peptides (thrombospondin-1, TSP-1; and endostatin) as well as pro-

115 mia-reperfusion injury is exacerbated by the thrombospondin-1-CD47 system through inhibition of nitri

116 is study, we investigate the function of the thrombospondin-1-like glycoprotein, Nel (neural epiderma

117 Renal IRI upregulated the thrombospondin-1-SIRP-alpha signaling axis and was assoc

118 CD47 is a receptor for the secreted protein thrombospondin-1.

119 ding activity and structural similarities to thrombospondin-1.

120 ive expression of angiogenic inhibitors like thrombospondin-1.

121 ain, but they do not hetero-oligomerize with thrombospondin-1.

122 r soluble P-selectin, platelet factor 4, and thrombospondin-1.

123 and (3) a stimulatory role for thrombin, the thrombospondin-1/CD36 axis and cyclooxygenase 1 in subse

124 on injury (IRI), which is exacerbated by the thrombospondin-1/CD47 pathway through inhibition of nitr

125 The results demonstrate that noncatalytic thrombospondin-1/cysteine-rich/spacer domains are princi

126 Replacing the thrombospondin-1/cysteine-rich/spacer domains of ADAMTS5

127 her a disintegrin and metalloproteinase with thrombospondin-13 activity and lower anti-a disintegrin

128 nti-a disintegrin and metalloproteinase with thrombospondin-13 antibody titers.

129 Hydrogen peroxide reduced thrombospondin 2 (an MMP-3 suppressor) expression in pro

130 a-1; tenascin C; collagen, type VI, alpha-3; thrombospondin 2; and von Willebrand factor) were verifi

131 transforming growth factor beta1 and beta2; thrombospondin 2; intercellular adhesion molecule 1; int

132 in vivo efficacy of intraluminal delivery of thrombospondin-2 (TSP-2) small interfering RNA (siRNA).

133 is regulated by multiple factors, including thrombospondin-2 (TSP2) and hypoxia/VEGF-induced activat

134 for higher levels of nerve growth factor and thrombospondin-2 (TSP2) by hES-RPE.

135 CM) abnormality to the bleeding diathesis in thrombospondin-2 (TSP2) knockout (KO) mice.

136 Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vasc

137 alpha2delta-1 and the synaptogenic domain of thrombospondin-2 was prevented by gabapentin.

138 -generated astrocytes express high levels of thrombospondin 4 (Thbs4), a secreted homopentameric glyc

139 eracts with the extracellular matrix protein thrombospondin 4 (TSP4), and antibodies to TSP4 neutrali

140 We recently reported that thrombospondin-4 (Thbs4) has a critical intracellular fu

141 Here we show that Thrombospondin-4 (Thbs4) regulates skeletal muscle integ

142 Thrombospondin-4 (TSP-4) expression increases dramatical

143 We found that in endothelial cells (EC) thrombospondin-4 (TSP-4), a secreted extracellular matri

144 nerve injury induces increased expression of thrombospondin-4 (TSP4) in spinal cord and dorsal root g

145 ion of a novel neuropathic pain contributor, thrombospondin-4 (TSP4), using a neuropathic pain model

146 oprecipitation could be demonstrated between thrombospondin-4 and alpha2delta-1 when co-transfected,

147 Thrombospondin-4 expression was reduced at the mRNA leve

148 is system to demonstrate an in vivo role for thrombospondin-4 in limb regeneration.

149 Matrilin-1, matrilin-4, epiphycan, and thrombospondin-4 levels were reduced in collagen IX null

150 We concentrated on thrombospondin-4, because, like alpha2delta-1, it is upr

151 Matrilin-4, collagen XII, thrombospondin-4, fibronectin, betaig-h3, and epiphycan

152 cells co-transfected with alpha2delta-1 and thrombospondin-4, there was a Mg(2+) -dependent reductio

153 but there was no co-immunoprecipitation with thrombospondin-4-EGF domain.

154 reproduced by the synaptogenic EGF-domain of thrombospondin-4.

155 XCL10xwomen (0.69), and the interaction term thrombospondin 4xmen (1.38).

156 3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the

157 ind that accumulation of thrombospondin-1 or thrombospondin-5 puncta within cell-derived ECM is contr

158 in (WGA) reactive glycans on fibronectin and thrombospondin-5 were preferentially bound by multimers

159 notype contained less of the cleaved form of thrombospondin-5, an ADAMTS7 substrate that had been sho

160 ic-for example, between thrombospondin-1 and thrombospondin-5.

161 d from anabolic remodeling linked to maximal thrombospondin and platelet-derived growth factor D expr

162 MTS-5 identified that the noncatalytic first thrombospondin and spacer domains mediate its endocytosi

163 duced expression of fibronectin, N-cadherin, thrombospondin, and the notch ligand jagged-1 in culture

164 ules, such as ECM metalloproteinase inducer, thrombospondins, and integrins, can further mediate cell

165 We have reported that astrocyte-secreted thrombospondins, and their target neuronal receptors (al

166 Thrombospondins are a family of stress-inducible secrete

167 In investigating how thrombospondins become retained within ECM and thereby a

168 al microscopy revealed that fibrin(ogen) and thrombospondin colocalized as "cap," a single patch on t

169 n and metalloproteinase" (ADAMs), ADAMs with thrombospondin domains (ADAM-TS), and Astacins are now r

170 For ADAMs with ThromboSpondin domains (ADAMTSs), there are biological a

171 MTSs (a disintegrin and metalloprotease with thrombospondin domains) are a family of enzymes with bot

172 or hUTC-secreted synaptogenic factors as the thrombospondin family proteins (TSPs), TSP1, TSP2, and T

173 he emergence of glia and the upregulation of thrombospondins in culture.

174 ccumulation and thereby the functionality of thrombospondins in ECM.

175 Astrocyte-secreted thrombospondins induce the formation of structural synap

176 pleiotropic functions, including adhesion to thrombospondin, inhibition of angiogenesis, transport of

177 lta-1 on feeding and implicate alpha2delta-1-thrombospondin interactions known to facilitate excitato

178 The incorporation of thrombospondins into extracellular matrix (ECM) as discr

179 ovel, conserved, surface-exposed site on the thrombospondin L-type lectin domain.

180 repeat domain, and a C terminus containing a thrombospondin-like type I repeat (TSR) domain.

181 This site acts to recruit thrombospondin molecules into ECM by intermolecular inte

182 s), a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) and the tissue inhibitors

183 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) has antithrombotic prop

184 a disintegrin-like and metalloprotease with thrombospondin motifs (ADAMTS family).

185 A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) constitute a family of en

186 Disintegrin-like And Metalloproteinase with ThromboSpondin motifs (ADAMTS) family of secreted metall

187 an A Disintegrin And Metalloproteinase with ThromboSpondin motifs (ADAMTS) gene, to the pathway.

188 as a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) metalloproteinases that m

189 ns, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), modulates structural pla

190 teinase (MMP)-13, a disintegrin and MMP with thrombospondin motifs (ADAMTS)-4, and type II collagen e

191 ), adamalysins (ADAMs), and adamalysins with thrombospondin motifs (ADAMTSs).

192 A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) cleaves von Willebra

193 A disintegrin and metalloprotease with thrombospondin motifs 13 (ADAMTS13) is a metalloprotease

194 13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) caused a dose-dependent reduct

195 ase a disintegrin and metalloproteinase with thrombospondin motifs 3 (ADAMTS3) and the secreted facto

196 fying a disintegrin and metalloprotease with thrombospondin motifs 4 (ADAMTS4) and miR-322 as potenti

197 Adamalysin-like metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) is a major aggrecan-d

198 and a disintegrin and metalloproteinase with thrombospondin motifs 5 and of the inflammatory factors

199 zyme, adamalysin-like metalloproteinase with thrombospondin motifs 5.

200 led a disintegrin and metalloproteinase with thrombospondin motifs [ADAMTS]) is responsible for endog

201 -5 (A disintegrin and metalloproteinase with thrombospondin motifs) degrades aggrecan, a proteoglycan

202 TS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) enzymes are secreted, multi-domai

203 TS (a disintegrin and metalloproteinase with thrombospondin motifs) family contribute to the cataboli

204 (A Disintegrin-like and Metalloprotease with Thrombospondin motifs) genes as central component of the

205 16 (a disintegrin and metalloproteinase with thrombospondin motifs) is a secreted mammalian metallopr

206 on of a disintegrin and metalloprotease with thrombospondin motifs-1 (ADAMTS1) and downregulated its

207 A disintegrin-like metalloproteinase with thrombospondin motifs-16 (Adamts16) is an important cand

208 ntify A disintegrin and metalloprotease with thrombospondin motifs-3 as a VEGF-C-activating protease

209 y the A disintegrin and metalloprotease with thrombospondin motifs-3 protease, resulting in the matur

210 and a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5 are cons

211 A disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5 are zinc

212 disintegrin-like and metalloproteinase with thrombospondin motifs-4) is a secreted proteinase involv

213 TS-5 (a disintegrin and metalloprotease with thrombospondin motifs-5) in the vasculature.

214 ron increased the amount of fibrin(ogen) and thrombospondin on the surface of the PS-positive platele

215 Thrombospondins participate in many aspects of tissue or

216 alpha2delta-1, a calcium channel subunit and thrombospondin receptor, in triggering overeating in mic

217 erythrocytic antigen insert multiple epitope-thrombospondin-related adhesion protein (ME-TRAP).

218 the preerythrocytic insert multiple epitope thrombospondin-related adhesion protein (ME-TRAP; n = 54

219 red with the vaccine candidate P. falciparum thrombospondin-related adhesion protein (PfTRAP) express

220 48-, sporozoite-specific protein 20318-325-, thrombospondin-related adhesion protein (TRAP) 130-138-,

221 he other inducing potent T-cell responses to thrombospondin-related adhesion protein (TRAP) by using

222 her subunit vaccines, such as virus-vectored thrombospondin-related adhesive protein (TRAP), provide

223 mune responses against Plasmodium falciparum thrombospondin-related anonymous protein (TRAP) in clini

224 protein (CSP), liver stage antigen 1 (LSA1), thrombospondin-related anonymous protein (TRAP), and cel

225 Surface-associated TRAP (thrombospondin-related anonymous protein) family protein

226 containing sporozoite-specific protein named thrombospondin-releated protein 1 (TRP1) is important fo

227 that the sporozoite protein with an altered thrombospondin repeat (SPATR) is a micronemal protein co

228 ied a disintegrin and metalloproteinase with thrombospondin repeat 7 (ADAMTS7) as a CTGF binding prot

229 the AP convertase is mediated by a single FP thrombospondin repeat and a small region in C3b.

230 tebrate host cells in malaria is mediated by thrombospondin repeat anonymous protein (TRAP).

231 that contains 19 NANP repeats followed by a thrombospondin repeat domain.

232 von Willebrand factor A (VWA) domain and six thrombospondin repeat domains (TSR1-6) in its ectodomain

233 We found that a thrombospondin-repeat containing sporozoite-specific pro

234 four C1ql proteins bind to the extracellular thrombospondin-repeat domain of BAI3 with high affinity,

235 as prevented by simultaneous addition of the thrombospondin-repeat fragment of BAI3, which binds to C

236 apoptotic cells through its conserved type I thrombospondin repeats and triggers their engulfment thr

237 Because thrombospondin repeats in other proteins have been shown

238 AMTS (a disintegrin and metalloprotease with thrombospondin repeats)-like family, a class of extracel

239 Glycoproteins (eg, thrombospondins, secreted protein acidic and rich in cys

240 onment of antiangiogenic proteins containing thrombospondin structural homology (TSR) domains.

241 spondins, with the interaction involving the thrombospondin synaptogenic domain and the alpha2delta-1

242 Thrombospondin (Thbs) proteins are induced in sites of t

243 We identified 7 O-fucosylation sites in the thrombospondin (TSP) type 1 repeats.

244 eract through integrin (Itg) ligands such as Thrombospondin (Tsp), while vertebrate muscles attach to

245 rpose of this study was to determine whether thrombospondin (TSP)-1 promotes macrophage activity and

246 that the prototypical matricellular protein thrombospondin (TSP)-1, a potent angiostatic molecule an

247 Thrombospondin (TSP)-2-null mice have an altered brain f

248 We show for the first time that a vertebrate thrombospondin, Tsp4b, is essential for muscle attachmen

249 Astrocyte-derived thrombospondins (TSPs) are likely responsible because TS

250 Thrombospondins (TSPs) are secreted extracellular matrix

251 Moreover, we identified thrombospondins (TSPs) as the hUTC-secreted factors that

252 Gabapentin antagonizes the interaction of thrombospondins (TSPs) with the alpha2delta-1 receptor,

253 omprising, in addition to IGFBP and vWC, the thrombospondin type 1 (TSP1) repeats are CCN1 degradome

254 eptor 1 (PLA2R1) and the recently identified thrombospondin type 1 domain-containing 7A (THSD7A) are

255 Thrombospondin type 1 domain-containing 7A (THSD7A) is a

256 Thrombospondin type 1 domain-containing 7A (THSD7A) is a

257 type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A).

258 egrin-like and metalloproteinase domain with thrombospondin type 1 motif (ADAMTS) proteases is requir

259 essed A Disintegrin And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13)-derived peptid

260 d (3) a disintegrin and metalloprotease with thrombospondin type 1 motif, 13 (ADAMTS13) activity >10%

261 such as ADAMTS13 (ADAM metallopeptidase with thrombospondin type 1 motif, 13) for coronary artery dis

262 disintegrin-like and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) revolu

263 f a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), a VWF

264 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity (>10%).

265 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as v

266 13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13), cleavage by whi

267 (a disintegrin and metalloproteinase, with a thrombospondin type 1 motif, member 13), resulting in fo

268 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).

269 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; the endogenous V

270 and metalloproteinase (reprolysin type) with thrombospondin type 1 motifs) proteins are necessary for

271 13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13) deficiency, pla

272 We have previously shown that the first thrombospondin type 1 repeat (TSR1, the central TSR) but

273 TS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat) cleaves multimers of von W

274 F) by A disintegrin and metalloprotease with thrombospondin type 1 repeats (ADAMTS13) under fluid she

275 ose is added to cysteine-rich domains called thrombospondin type 1 repeats (TSRs) by protein O-fucosy

276 Thrombospondin type 1 repeats (TSRs) occur in diverse pr

277 cose disaccharide to a consensus sequence in thrombospondin type 1 repeats (TSRs) of several proteins

278 ER quality control mechanism for folding of thrombospondin type 1 repeats by protein O-fucosyltransf

279 ainst A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats, 13 (ADAMTS13).

280 icted epidermal growth factor domain and two thrombospondin type 1 repeats, implying a role in host c

281 cy of a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13).

282 TS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) proteolysis of

283 TS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), the specific

284 n and A Disintegrin and Metalloprotease with Thrombospondin type 1 repeats-13 (ADAMTS-13) to 60%, 24%

285 s a common posttranslational modification of thrombospondin type 1 repeats.

286 (a disintegrin and metalloproteinase with a thrombospondin type I motif, member 13).

287 Tandem von Willebrand factor A (VWA) and thrombospondin type I repeat (TSR) domains in TRAP conne

288 rane proteins UNC-40/DCC and MIG-21, a novel thrombospondin type I repeat containing protein, act red

289 ld in binding to the membrane proximal sixth thrombospondin type I repeat domain of MIC2.

290 disintegrin-like and metalloproteinase with thrombospondin type I repeats 13) accounts for this proc

291 The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) are

292 Mass spectrometry identified this antigen as thrombospondin type-1 domain-containing 7A (THSD7A).

293 ntegrin-like and metalloprotease domain with thrombospondin type-1 motif, number 13) on secretion fro

294 eas a disintegrin and metalloproteinase with thrombospondin type-1 repeats 13 (ADAMTS-13) cleaves VWF

295 TS13 (a disintegrin and metalloprotease with thrombospondin type-1 repeats)-mediated proteolysis.

296 e containing tandem repeats, region III, and thrombospondin type-I repeat (TSR) of CS is efficacious

297 ntegrin-like And Metalloprotease domain with ThromboSpondin-type 1 motifs) which we demonstrated is e

298 date, little is known about the diversity of thrombospondin-type-1 repeat (TSR) domain proteins in ba

299 We therefore examined whether interaction of thrombospondin with alpha2delta-1 might reciprocally inf

300 alpha2delta-1 was identified as a ligand of thrombospondins, with the interaction involving the thro